Quality Assurance of HCV [hepatitis C virus]-Therapy With PegIntron Plus Rebetol in Drug-Substituted Patients - SUPPORT Project Post-Marketing Surveillance Study.
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms SUPPORT
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 31 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 31 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2008 Planned end date changed from Jan 2009 to Sep 2009 as reported by ClinicalTrials.gov.